The Week

Alaunos Therapeutics (TCRT) rallied 234.69% this week to close at $2.63, while the S&P 500 fell 1.95% and the stock outperformed by about 236.64 percentage points. The move was anything but one-directional. It opened Monday at $0.7755 and ended that day at $1.05. Tuesday was the explosive session: the stock spiked to $4.32 intraday and closed at $3.03 on volume of roughly 257m shares. Wednesday briefly printed the week’s high of $4.40 before sliding back to close at $2.07. Thursday and Friday saw choppy trading above the $2 level, finishing at $2.63. The week’s amplitude reached 468.09%.

Key Events

This week’s storyline centred on an acquisition and financing. On Tuesday 13 October, Alaunos announced it would acquire Velaris Therapeutics and simultaneously complete a major financing, described in reports as a $350m raise. The stock jumped more than 78% intraday that day and closed 188.57% higher for the session. Follow-up coverage on Wednesday and Thursday kept returning to the same acquisition and funding progress, with the company expected to integrate Velaris’ assets and pipeline.

Alongside the rally sat a counter-thread: several reports noted the company had also received a Nasdaq delisting notice. A Friday 16 October intraday update said Alaunos was up more than 30%, but the delisting risk remained unresolved. Overnight action on Friday was also volatile: TCRT rose roughly 29% to 32% in the night session, with some reports attributing the move more to speculative flows than fresh fundamental news. Overall, the week’s news was tightly concentrated on the acquisition close and financing, with the delisting notice running in parallel.

Analyst Ratings

Coverage is currently limited to one institution. That analyst assigns a hold rating; there are no buy, overweight, strong buy, underweight or sell ratings on file. The consensus rating is hold, with a consensus target price of $205.4999. Against the week’s close of $2.63, the consensus target sits roughly 7713.68% above spot. The target is aggregated from data dated February 2024, so its gap to the current price reflects a much older valuation window rather than this week’s updates. With only one covering institution, industry ranking adds little context, and no new rating changes were reported this week.

The Week Ahead

Next week’s macro calendar leans towards US housing and energy releases: the NAHB housing market index is due Monday 19 October, with both prior and forecast at 32; housing starts annualised and building permits annualised arrive Tuesday 20 October, with prior readings of 1.275 and 1.403, and forecasts of 1.305 and 1.395; Wednesday 21 October brings EIA weekly crude oil inventories and Cushing inventories. For the company itself, attention is more likely to rest on any evidence of post-acquisition integration progress and any follow-through on the Nasdaq delisting notice. There is no scheduled company earnings date disclosed for next week.

In Short

The week’s signals pull in opposite directions. The Velaris acquisition and $350m financing drew speculative attention, lifting the stock from below $1 to above $2 and producing a weekly gain above 200%. On the other side sits the Nasdaq delisting notice and a thin analyst base — one hold rating with an outdated consensus target — leaving the price with little institutional anchoring. The latest daily flow snapshot also shows dispersion rather than a clean direction: large-lot buying was slightly below large-lot selling, while medium and small segments showed net inflows. What matters next is the pace at which the acquired assets are actually integrated, and how the exchange’s delisting process unfolds. The market is pricing a mix of those two forces rather than agreeing on a single bullish or bearish signal.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.